A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

PD-0332991 may work in cancer by stopping cancer cells from multiplying. PD-0332991 is in a new class of drugs called cyclin-dependent kinase (CDK inhibitors). This research study is the first time that PD-0332991 will be given to people. PD-0332991 is taken by mouth daily.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Cyclin-Dependent Kinase Inhibitor Proteins; Palbociclib

Criteria

Inclusion Criteria:

• Advanced solid tumors (excluding SCLC and retinoblastoma) or follicular of diffuse large cell non-Hodgkin's lymphoma, histologically or cytologically proven at diagnosis which is refractory to or intolerant of established therapy know to provide clinical benefit for their condition; tumors must express Rb

• Adequate blood cell counts, kidney function and liver function and and ECOG score of 0, 1, or 2.

• Patients may have to have tumor biopsy before and after treatment.

Exclusion Criteria:

• Prior stem cell or bone marrow transplant

• Uncontrolled infection, unstable or sever intercurrent medical condition, or current drug or alcohol abuse

• Active or unstable cardiac disease or history of heart attack within 6 months